Lin Shen
Peking University(CN)Peking University Cancer Hospital(CN)
Publications by Year
Research Areas
Gastric Cancer Management and Outcomes, Colorectal Cancer Treatments and Studies, HER2/EGFR in Cancer Research, Cancer Immunotherapy and Biomarkers, Lung Cancer Treatments and Mutations
Most-Cited Works
- → First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial(2021)2,783 cited
- → Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study(2017)250 cited
- → Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study)(2014)241 cited
- → Dynamic monitoring of circulating tumour cells to evaluate therapeutic efficacy in advanced gastric cancer(2016)100 cited
- → Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study(2017)86 cited
- → Establishment and characterization of patient-derived tumor xenograft using gastroscopic biopsies in gastric cancer(2015)75 cited
- → Circulating tumor DNA functions as an alternative for tissue to overcome tumor heterogeneity in advanced gastric cancer(2017)69 cited
- → Pertuzumab (P) + trastuzumab (H) + chemotherapy (CT) for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (mGC/GEJC): Final analysis of a Phase III study (JACOB)(2017)58 cited
- → Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial(2017)42 cited
- → Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2‐positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial(2019)29 cited